Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. (Q48686121)

14 February 2018

title

Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. (English)

1 reference

14 February 2018

1 reference

Anjana Bose

1

1 reference

14 February 2018

Joyce Tsai

series ordinal

2

1 reference

14 February 2018

Dayong Li

series ordinal

3

1 reference

14 February 2018

publication date

1 June 2012

1 reference

14 February 2018

Clinical Drug Investigation

published in

1 reference

14 February 2018

volume

32

1 reference

14 February 2018

page(s)

373-385

1 reference

14 February 2018

issue

6

1 reference

14 February 2018

The burden of severe depression: a review of diagnostic challenges and treatment alternatives

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

The onset of effect for escitalopram and its relevance for the clinical management of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11631890-000000000-00000

21 January 2018

12 December 2020

Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.

1 reference

12 December 2020

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

Is there a delay in the antidepressant effect? A meta-analysis

1 reference

12 December 2020

STAR*D: revising conventional wisdom.

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.

1 reference

12 December 2020

Are SNRIs more effective than SSRIs? A review of the current state of the controversy.

1 reference

12 December 2020

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis

1 reference

12 December 2020

Effective Dose of Escitalopram in ModerateversusSevere DSM-IV Major Depression

1 reference

12 December 2020

Treatment of severe depression

1 reference

12 December 2020

10.2165/11631890-000000000-00000

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

22559255

1 reference

14 February 2018